



Dr Alan So

Associate Professor - The University Of British Columbia, Vancouver, Canada

Alan So currently leads the Clinical Trials Unit at the Vancouver Prostate Cancer and is the Chair of the Urology Surgical Tumour Group at the British Columbia Cancer Agency. Dr So is active in clinical trials across Canada and is a member of National Cancer Institute of Canada GU Clinical Trials Group and Canadian Uro-Oncology Group.

Dr. So's current research focuses on the study of development of novel therapeutics for bladder cancer and determination of the functional role of GLI1/2 in the progression of prostate cancer to its lethal stage of androgen independence as well as the implication of bone metastasis in prostate cancer progression. He has characterized the functional role of different survival genes (including clusterin and Hsp27) in different tumor models (prostate, breast, lung, and bladder) in cancer progression. His current research focuses on discovery and development of novel agents to treat bladder cancer as well as development of the mechanisms of treatment resistance in renal cell carcinoma.

He is active in clinical trials across Canada and is a member of National Cancer Institute of Canada GU Clinical Trials Group and Canadian Uro-Oncology Group. Currently, he leads the Clinical Trials Unit at the Vancouver Prostate Cancer and is the Chair of the Urology Surgical Tumour Group at the BC Cancer Agency.